×

Engraftment of stem cells with a combination of an agent that targets stem cells and modulation of immunoregulatory signaling

  • US 10,406,179 B2
  • Filed: 08/26/2015
  • Issued: 09/10/2019
  • Est. Priority Date: 08/26/2014
  • Status: Active Grant
First Claim
Patent Images

1. A method of hematopoietic stem cell engraftment in a mammal, the method comprising:

  • contacting said mammal concomitantly with (i) a monoclonal antibody specific for CD117 and (ii) an agent that blocks interaction between CD47 and SIRPα

    , wherein the agent is selected from an anti-CD47 antibody, an anti-SIRPα

    antibody, a soluble SIRPα

    polypeptide or a fusion protein comprising a SIRPα

    polypeptide;

    in a dose effective in ablating hematopoietic stem cells from bone marrow of said mammal; and

    introducing exogenous hematopoietic stem cells to said mammal, wherein the exogenous hematopoietic stem cells engraft to provide for long-term multilineage hematopoietic engraftment.

View all claims
  • 1 Assignment
Timeline View
Assignment View
    ×
    ×